CytoVeris’ Smart Cancer Imaging Solution

Proving what’s possible during surgery.

CytoVeris’ Smart Cancer Imaging Solution

Proving what’s possible during surgery.

OUR MISSION

To enhance the quality of intraoperative cancer detection through AI-powered imaging solutions, improving outcomes and accessibility for surgeons and patients.

Today, ensuring complete resection of breast cancer is challenging, often leading to poor outcomes and economic burden across the healthcare continuum.

Up to

0 %
Percent
of breast cancer resection have cancer left in the cavity

Estimated

$ 0 B
Dollars
in medical expenditures on breast cancer in the United States

Greater than

$ 100 B
Dollars
cost per year in secondary surgeries for breast cancer
Our aim is to empower surgeons to make more reliable and accurate real-time intraoperative decisions for their patients, beginning with breast cancer.

Reduction of up to

50%

of positive post-operative margins

Cost Savings of

$500M

to the U.S. healthcare system

* Based on feasibility studies  that indicate a reduction of positive post-operative margins of up to 60%, which would result in a direct cost savings to the U.S. healthcare system of $600 million per year.

Enabling SMARTER, more EFFICIENT, and more EFFECTIVE surgical visualization

The Tumor Margin Assessment and Profiling System,  TumorMAP™ is a multispectral imaging (MSI), Ultra high-definition (UHD), real-time intraoperative cancer imaging solution. TumorMAP produces an ultra-violet-excited autofluorescence image that enables surgeons to visually assess tissue that is indicative of cancer, based on changes in metabolism and tissue microstructure between healthy and unhealthy tissues.

All without the use of an imaging agent

Real-Time

Actionable Feedback to Surgeons

PRECISE

Tissue Margin Accuarcy

Workflow

Bringing the greatest effectiveness

Reduction

Of cost of breast cancer surgery

better outcomes

With fewer second surgeries

>> CLICK HERE  TO LEARN MORE ABOUT ONCOSIGHT AI

OncoSIGHT AI™ is a proprietary, next generation tissue characterization algorithm that provides a safer, smarter and more reliable visualization of cancerous tissue.

CytoVeris’ Platform Technology, TumorMAP™ powered by OncoSight AI™, relies on the intersection of natural characteristics of tissue and AI, and is in development to make a difference for patients across multiple disease areas.

Indication

Pre-clinical research

OncoSIGHT AI training
OncoSIGHT AI validation

Feasibility Study

Pivotal Study

FDA Approval

breast
bladder
liver
Scroll to Top

“CYTOVERIS NAMED "MURPHY'S INNOVATOR OF THE MONTH"

CytoVeris is a medical device company developing optical smart cancer imaging technologies designed to improve the clinical outcomes of patients undergoing certain cancer removal procedures by using enhanced clinical decision-making during surgery.